[1]樊晓栋,姜庆,王家武.新辅助化疗对肌层浸润性膀胱癌预后影响的Meta分析[J].第三军医大学学报,2011,33(02):196-199.
　Fan Xiaodong,Jiang Qing,Wang Jiawu.Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study[J].J Third Mil Med Univ,2011,33(02):196-199.
点击复制

新辅助化疗对肌层浸润性膀胱癌预后影响的Meta分析(/HTML )
分享到：

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
33卷
期数:
2011年第02期
页码:
196-199
栏目:
论著
出版日期:
2011-01-30

文章信息/Info

Title:
Efficacy of neoadjuvant chemotherapy on prognosis of muscle-invasive bladder cancer: a Meta-analysis study
作者:
樊晓栋; 姜庆; 王家武
重庆医科大学附属第二医院泌尿外科
Author(s):
Fan Xiaodong;  Jiang Qing;  Wang Jiawu
Department of Urology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China
关键词:
新辅助化疗; 肌层浸润性膀胱癌; Meta分析
Keywords:
neoadjuvant chemotherapy; muscle-invasive bladder cancer; Meta-analysis
分类号:
R195.1;R730.53;R737.14
文献标志码:
A
摘要:
目的   评价新辅助化疗对肌层浸润性膀胱癌患者预后的影响。   方法   通过PubMed、Cochrane library、万方、康健、CBMdisc、EMBASE等数据库收集国内外已发表的相关前瞻性随机对照研究，按预设的标准进行筛选，共12个研究符合纳入标准，总样本量3 286例，新辅助治疗组1 636例，对照组1 650例，对纳入研究进行质量评价，并提取数据进行Meta分析。   结果   新辅助化疗组与对照组相比，死亡风险优势比0.85（95% CI 0.73～0.98，P=0.03）。将12个纳入研究按新辅助化疗方案进行亚组分析，单用铂剂组显示新辅助化疗并没有降低患者死亡风险，而以铂剂为基础的多药联合新辅助化疗可降低患者死亡风险（OR 0.79，95% CI 0.67～0.92，P=0.000 4）。   结论   新辅助化疗，尤其是以铂剂为基础的联合化疗方案，适用于肌层浸润性膀胱癌的治疗，可改善预后。
Abstract:
Objective   To evaluate the effect of neoadjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer.    Methods   Published prospective randomized controlled trials (RCT) on neoadjuvant chemotherapy for muscle-invasive bladder cancer were searched and screened in Pubmed, EMBASE, CBMdisc, Cochrane library and Wanfang databases under preset standards. The data from eligible studies were pooled through Meta-analysis.    Results   Totally 12 trials including 3 286 patients were eligible to the criteria (1 636 in study group and 1 650 in control group).The odds radio of all trails tended to favour neoadjuvant chemotherapy (OR=0.85, 95% CI 0.73 to 0.98, P=0.03). Platinum-based combination chemotherapy showed a significant reduction in risk of death（OR=0.79, 95% CI=0.67 to 0.92, P=0.0004), but there was no evidence to support the use of single-agent platinum.     Conclusions   Neoadjuvant chemotherapy especially platinum-based combination chemotherapy is beneficial to muscle-invasive bladder cancer patients.

相似文献/References:

[1]张毅,周艳,郭美琴,等.全乳大切片观察新辅助化疗后乳腺癌浸润性生长特征变化[J].第三军医大学学报,2007,29(21):2083.
　ZHANG Yi,ZHOU Yan,GUO Mei-qin,et al.Infiltrating characteristics of breast cancer after neoadjuvant chemotherapy: whole breast serial subsection observation[J].J Third Mil Med Univ,2007,29(02):2083.
[2]田桂兰.手术治疗Ⅱb期宫颈癌的疗效评价[J].第三军医大学学报,2006,28(07):738.
[3]梁后杰,赵晓昕.结直肠癌肝转移新辅助化疗的共识与争议[J].第三军医大学学报,2009,31(01):26.
[4]王莉,刘风花,刘若男.新辅助化疗对宫颈鳞癌细胞增殖与凋亡的影响[J].第三军医大学学报,2005,27(15):1599.
[5]王姝姝,张毅,齐晓伟,等.乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系[J].第三军医大学学报,2010,32(21):2336.
　Wang Shushu,Zhang Yi,Qi Xiaowei,et al.Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer[J].J Third Mil Med Univ,2010,32(02):2336.
[6]李蕊,刘斌,梅耀宇,等.新辅助化疗对早期巨块型宫颈癌淋巴结转移及生存的意义[J].第三军医大学学报,2011,33(12):1289.
　Li Rui,Liu Bin,Mei Yaoyu,et al.Significance of neoadjuvant chemotherapy for lymphatic metastasis and survival in patients with early bulky cervical cancer[J].J Third Mil Med Univ,2011,33(02):1289.
[7]王明浩,杨新华,张毅,等.乳腺癌外周血循环肿瘤细胞变化与新辅助化疗效果的关系[J].第三军医大学学报,2013,35(11):1148.
　Wang Minghao,Yang Xinhua,Zhang Yi,et al.Relationship of peripheral blood circulating tumor cells with therapeutic effect of neoadjuvant chemotherapy in breast cancer: report of 70 cases[J].J Third Mil Med Univ,2013,35(02):1148.
[8]程鸿,姜军,杨新华,等.不同方案新辅助化疗对乳腺癌激素受体表达的影响[J].第三军医大学学报,2007,29(10):973.
　CHENG Hong,JIANG Jun,YANG Xin-hua,et al.Influence of neoadjuvant chemotherapy of different regimen on expression of hormonal receptors in breast cancer[J].J Third Mil Med Univ,2007,29(02):973.
[9]余昆,代林,刘胜,等.膀胱部分切除术与根治性全膀胱切除术治疗局限性肌层浸润性膀胱癌的临床分析[J].第三军医大学学报,2018,40(02):169.
　YU Kun,DAI Lin,LIU Sheng,et al.Comparison of therapeutic effects of partial cystectomy versus radical cystectomy for localized muscle invasive bladder cancer[J].J Third Mil Med Univ,2018,40(02):169.
[10]唐铃丰,舒秀洁,严萍,等.雌激素受体阳性型乳腺癌新辅助化疗效果的影响因素及疗效预测[J].第三军医大学学报,2020,42(23):2341.
　TANG Lingfeng,SHU Xiujie,YAN Ping,et al.Influencing factors and efficacy prediction of neoadjuvant chemotherapy for ER positive breast cancer[J].J Third Mil Med Univ,2020,42(02):2341.

更新日期/Last Update: 2011-01-19